InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,090.05
(
1.08%
)
US TECH 100
17,147.60
(
0.97%
)
Dow Jones
38,310.62
(
1.31%
)
Brent Oil
83.64
(
-2.63%
)
Bitcoin
58,557.88
(
-3.38%
)
Post# of 4967026
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

TheFinalCD

Send PM Follow Ignore
Followers 4053
Posts 151254
Boards Moderated 4
Alias Born 08/05/2009

TheFinalCD

Member Level

Re: Drugdoctor post# 4088323

Monday, 03/20/2017 8:44:44 AM

Monday, March 20, 2017 8:44:44 AM

Post# of 4967026
GNMX 2.16 PHILADELPHIA, PA--(Marketwired - Mar 20, 2017) -

Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose (400 mg BID)
Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo)
Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo)
Clear signal of efficacy and benefit to patients
ADHD-RS response rate 70% (p=0.0067 vs placebo)
CGI-I response rate 57% (p=0.0155 vs placebo)
ADHD-RS response rate 70% (p=0.0067 vs placebo)
CGI-I response rate 57% (p=0.0155 vs placebo)
Well tolerated with no serious adverse events
Conference call scheduled for 8:30 AM ET
http://finance.yahoo.com/news/aevi-genomic-medicine-provides-top-110000841.html


Always consult an Investment Professional, all communications
about stocks from me are my own opinions, and not for investing
decisions

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up